China's homegrown drug Sintilimab designed for treating relapsed or refractory¹ classic Hodgkin lymphoma has won international recognition, with its clinical trial research published as the cover paper in the January issue of The Lancet Haematology.

 

中国自主研发的用于治疗复发或顽固性霍奇金淋巴瘤的药物信迪利单抗获得国际认可，其临床试验研究刊登在一月《柳叶刀血液学》封面上。
 

 

Hodgkin lymphoma is a rare malignant² lymphoma that occurs mostly in young people between the ages of 20 and 40. Although the cure rate of early treatment is high, patients have a 20 percent chance of recurrence³ after their first treatment. Patients with relapsed or refractory classic Hodgkin lymphoma lack effective treatment in China.

 

Sintilimab, an anti-PD-1 drug, is a kind of checkpoint inhibitor, an emerging anti-cancer therapeutic⁴ modality that boosts the immune system to help the body target and kill tumors.

 

Professor Shi Yuankai from the Cancer Hospital, Chinese Academy of Medical Sciences, led the clinical research, which enrolled⁵ 96 patients with relapsed or refractory classic Hodgkin's lymphoma from 18 hospitals in China.

 

Results showed that Sintilimab has favorable activity and acceptable toxicity⁶ in Chinese patients with relapsed or refractory classical Hodgkin lymphoma, with 80.4 percent of the patients showing an objective response.

 

Stephen M Ansell from the Division of Hematology at the Mayo Clinic commented that Sintilimab is a "highly effective treatment which potentially improves the outcomes of patients with classical Hodgkin lymphoma worldwide."

点击收听单词发音